Compare ASR & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASR | ABVX |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | Mexico | France |
| Employees | 1882 | 67 |
| Industry | Aerospace | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 9.7B |
| IPO Year | N/A | N/A |
| Metric | ASR | ABVX |
|---|---|---|
| Price | $295.72 | $114.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $365.00 | $131.31 |
| AVG Volume (30 Days) | 59.0K | ★ 767.5K |
| Earning Date | 04-22-2026 | 03-23-2026 |
| Dividend Yield | ★ 12.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.44 | $52.14 |
| Revenue Next Year | $9.69 | $4,132.27 |
| P/E Ratio | $18.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $292.35 | $5.59 |
| 52 Week High | $381.52 | $148.83 |
| Indicator | ASR | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 34.88 | 45.18 |
| Support Level | N/A | $107.29 |
| Resistance Level | $318.64 | $129.73 |
| Average True Range (ATR) | 6.82 | 4.94 |
| MACD | -0.18 | -0.04 |
| Stochastic Oscillator | 11.18 | 39.77 |
Grupo Aeroportuario del Sureste SAB de CV and its subsidiaries hold concessions to operate, maintain, and develop airports in the southeast region of Mexico. As an operator of airports, it charges airlines, passengers, and other users fees for using the airports' facilities. The group also derives rental and other income from commercial activities conducted at its airports, such as the leasing of space to restaurants and retailers. The company's operating segments are Cancun, which generates majority revenue, Aerostar, Airplan, Merida, Villahermosa, Holding and Services, and Others.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.